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Background: Preclinical data support a key role for the human epidermal growth
factor receptor 3 (HER3) pathway in hormone receptor (HR)–positive breast cancer.
Recently, new HER3 directed antibody drug conjugates have shown activity in
breast cancer. Given the need to better understand the molecular biology, tumor
microenvironment, and mechanisms of drug resistance in breast cancer, we designed
this window-of-opportunity study with the HER3 directed antibody drug conjugate
patritumab deruxtecan (HER3-DXd; U3-1402).
Trial Design: Based on these data, a prospective, multicenter, single-arm,
window-of-opportunity study was designed to evaluate the biological
effect of patritumab deruxtecan in the treatment of naïve patients with
HR-positive/HER2-negative early breast cancer whose primary tumors are
≥1 cm by ultrasound evaluation. Patients will be enrolled in four cohorts
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according to the mRNA-based ERBB3 expression by central assessment. The primary
endpoint is a CelTIL score after one single dose. A translational research plan is also
included to provide biological information and to evaluate secondary and exploratory
objectives of the study.
Trial Registration Number: EudraCT 2019-004964-23; NCT number: NCT04610528.
Keywords: Breast Cancer, ERBB3, HER3, U3-1402, patritumab deruxtecan, HER3-DXd, CelTIL Score
INTRODUCTION
HER3, encoded by the ERBB3 gene, is broadly expressed in
various types of human cancer. HER3 has been associated with
poor patient outcomes (1) and therapeutic agent resistance,
including resistance to anti-EGFR, anti-HER2 inhibitors (2),
and endocrine therapy (3, 4). HER3 belongs to the type I
transmembrane tyrosine kinase family of receptors and activates
intracellular signaling pathways, mainly the PI3K/AKT and
MAPK/ERK pathways, upon dimerization with other HER
family members (2, 5). These observations have resulted in the
development of investigational HER3 directed agents in HER3-
expressing breast cancer and other solid tumors.
Patritumab deruxtecan (HER3-DXd; U3-1402), a potential
first-in-class HER3 directed antibody drug conjugate (ADC),
is currently under development to act on these previously
mentioned targets (6). In addition to its antitumor efficacy by
binding HER3 ligand and the release of the cytotoxic payload
in the tumor cells (7), patritumab deruxtecan enhanced the
infiltration of innate and adaptive immune cells in preclinical
models (8). These preclinical data have shown that patritumab
deruxtecan can elicit potent antitumor immunity even in the
setting of tumors insensitive to PD-1 and PD-L1 immune
checkpoint inhibitors and that its efficacy is more pronounced
in the presence of PD-1 inhibition, suggesting that patritumab
deruxtecan sensitizes insensitive tumors to PD-1 blockade and
has synergistic effects (8).
In the clinical setting, an early report of a clinical
trial suggested that patritumab deruxtecan could be safely
administered and it demonstrated promising antitumor efficacy
(the overall response and the disease control rate were 42.9
and 90.5%, respectively) in heavily pretreated HER3-expressing
metastatic breast cancer (9); these results are in accordance with
more recent preliminary data from heavily pretreated EGFR-
mutated non-small cell lung carcinoma patients, in whom the
overall response rate was 25%, and the disease control rate was
70% (10).
Although no validated HER3 assay has been established
to date, recent studies support the role of HER3
immunohistochemistry (IHC) as a potential biomarker (11–13).
However, there are important limitations with IHC-based
assays, such as different sensitivities of the antibodies used,
their low dynamic range, their subjectivity in scoring, and their
difficulty in establishing suitable cut-offs. Therefore, clinical
implementation of a robust genomic assay would represent an
important advancement. To overcome these limitations, we plan
to test the prospective use of an mRNA-based ERBB3 expression
assay using the nCounter platform (Nanostring Technologies,
Seattle, USA) developed by our group (14).
The role of the host immune system in breast cancer is
becoming an important topic to study for several reasons. First,
the immune response has a fundamental role in the efficacy
of drug therapy. In all breast cancer subtypes, baseline high
TIL grade is associated with a significantly higher pCR rate
after neoadjuvant chemotherapy (15). Second, the recent success
of therapeutic agents capable of activating immune responses
to cancer, such as anti-PD1/PDL1 or anti-CTLA4 inhibitors,
allows innovative treatment strategies (16). Third, high tumor-
infiltrating lymphocytes (TILs) counts and immune-related gene
expression signatures in the primary tumor are consistently
associated with better survival in triple-negative breast cancer
and HER2-positive breast cancer (15, 17–19). On the other hand,
the prognostic value of assessing TILs in HR-positive/HER2-
negative breast cancer remains unclear according to a few studies
(15, 20).
The TOT-HER3 (a window-of-opportunity study of
patritumab deruxtecan, a HER3 directed ADC in operable
breast cancer according to ERBB3 expression) trial is designed
to assess whether a single dose of patritumab deruxtecan
can increase immune infiltration and the lysis of tumor cells
during short-term preoperative treatment in hormone receptor
(HR)-positive/HER2-negative primary breast cancer. Short-term
preoperative studies are a validated strategy for evaluating
the impact of targeted therapies using the decrease in tumor
cellularity and the increase in immune infiltration as a surrogate
endpoint of treatment benefit (21, 22). The primary endpoint of
TOT-HER3 is changes in the CelTIL score, a novel combined
biomarker based on stromal TILs and tumor cellularity. Access
to tumor tissue before and after the investigational treatment
enables comprehensive analysis of biomarker changes, thus
providing critical insights into the optimal patient population,
biomarker predictive value, and potential mechanisms of
primary resistance (23, 24).
METHODS
Study Design and Treatment
This is a prospective, multicenter, single-arm, window-of-
opportunity study evaluating the biological effect of patritumab
deruxtecan in treatment naïve patients with early breast cancer,
whose primary tumors are ≥1 cm by ultrasound evaluation
(Figure 1). The study will include up to 80 patients with HR-
positive/HER2-negative tumors.
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FIGURE 1 | TOT-HER3 trial design.
TABLE 1 | Main/key eligibility criteria.
Inclusion Criteria Exclusion criteria
1. Written informed consent form.
2. Premenopausal or post-menopausal women and men, age ≥ 18 years.
3. ECOG Performance Status 0–1.
4. Histologically confirmed non-metastatic primary invasive adenocarcinoma of
the breast untreated and recently diagnosed, with all the following
characteristics:
- At least one lesion that can be measured in at least 1 dimension with ≥ 1 cm in
the largest diameter measured by ultrasound.
- Absence of distant metastasis (M0) as determined by institutional practice.
- in the case of a multifocal or multicentric tumor, the largest lesion must be
≥1 cm and designated the “target” lesion for all subsequent tumor evaluations
and biopsies.
5. Patient must have biopsiable disease.
6. Estrogen (ER)-positive and/or Progesterone (PgR)-positive and
HER2-negative tumor by the most recent American Society of Clinical
Oncology—College of American Pathologists (ASCO-CAP) guidelines: ER
and PgR defined as IHC nuclear staining >1% and HER2 negative locally
assessed.
7. Ki67% ≥ 10% locally assessed.
8. Available pretreatment FFPE core needle biopsy evaluable for PAM50 and
ERBB3 mRNA expression.
9. Baseline LVEF ≥ 50%
10. Adequate organ functions
11. Absence of any psychological, familial, sociological, or geographical
condition potentially hampering compliance with the study protocol and
follow-up schedule; those conditions should be discussed with the patient
before registration in the trial.
1. Inoperable locally advanced or inflammatory (i.e., inoperable stage III) breast
cancer.
2. Bilateral invasive breast cancer.
3. Patients in whom a primary tumor excisional biopsy was performed.
4. Any prior treatment for primary actual invasive breast cancer.
5. Prior treatment with a HER3 antibody, topoisomerase I inhibitor, with an ADC
that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g.,
DS-8201) and with a govitecan derivative (e.g., IMMU-132).
6. Medical history of symptomatic congestive heart failure or serious cardiac
arrhythmia requiring treatment; myocardial infarction within 6 months prior to
enrolment or unstable angina.
7. QT interval corrected using Fridericia’s formula to >450ms in males and >
470ms in females.
8. Any factor that increases the risk of corrected QT interval prolongation or risk
of arrhythmic events, such as congenital long QT syndrome, family history of
long QT syndrome, or unexplained sudden death under 40 years of age in
first-degree relatives.
9. Medical history of clinically significant lung diseases or who are suspected to
have these diseases by imaging at the screening period.
10. Clinically significant corneal disease.
11. Known hypersensitivity to either the drug substance components or inactive
ingredients in the drug product or history of severe hypersensitivity reactions
to other monoclonal antibodies.
12. Clinically severe pulmonary compromise resulting from intercurrent
pulmonary illnesses including, but not limited to, any underlying pulmonary
disorder and any autoimmune, connective tissue, or inflammatory disorders
with potential pulmonary involvement or prior pneumonectomy.
Adult female patients (≥18 years old) with pre/post-
menopausal status will be eligible if they have not been
previously treated and have histologically confirmed stage I–
IIIA invasive breast cancer, with primary tumors equal to or
larger than 1 cm in diameter (asmeasured by ultrasound), clinical
nodal status of 0–2, HR-positive and HER2-negative according
to ASCO/CAP guidelines, and Ki67% ≥ 10% determined
locally. Patients should also have an Eastern Cooperative
Oncology Group (ECOG) performance status of 0–1 and
adequate hematological counts, hepatic and renal function,
and left ventricular ejection fraction ≥ 50%. Patients will
be excluded if they have received prior anticancer therapy.
Detailed inclusion and exclusion criteria can be found in
Table 1.
All patients will undergo pretreatment tumor tissue
acquisition. Central determination of ERBB3 mRNA expression
will be performed in FFPE core biopsies, and patients will be
enrolled in four cohorts, according to the expression of ERBB3
based in quartiles and defined by the pre-specified cutoffs, to
ensure a broad representation of HR-positive/HER2-negative
tumors with different ERBB3 expression. The number of slots
available per cohort will be limited to 20 patients each.
After confirmation of all the eligibility criteria, patients will
be enrolled, and a single dose of patritumab deruxtecan will be
Frontiers in Oncology | www.frontiersin.org 3 April 2021 | Volume 11 | Article 638482
Pascual et al. TOT-HER3 Study (SOLTI-1805)
administered by intravenous infusion at a dose of 6.4 mg/kg.
A second optional biopsy will be performed in the same lesion
3–7 days after patritumab deruxtecan’s administration. A third
biopsy post-treatment of the same lesion will be mandatory 21
(±3) days after the administration of patritumab deruxtecan,
independently of the subsequent treatment. Thereafter, patients
will be considered either for definitive surgery or primarymedical
treatment (e.g., neoadjuvant chemotherapy) at the discretion of
the treating physician.
Primary Endpoint—The CelTIL Score
To answer the primary objective of the trial, we will evaluate
CelTIL score differences between baseline and post-treatment
samples in all patients regardless of their ERBB3 mRNA
expression. The CelTIL score is based on the percentage (%) of
tumor cellularity and the % of stromal TILs. Histopathologic
analysis of the proportion of TILs will be done in whole sections
of tumor tissue stained with hematoxylin and eosin (H&E). TILs
will be quantified according to the 2014 guidelines developed by
the International TILs Working Group (25). Percentages of TILs
and tumor cellularity at baseline and D21 will be scored in slides
of core biopsies from patients enrolled in the trial blinded from
clinic–pathologic and outcome data.
The CelTIL score was developed based on day 15 tumor
samples from the PAMELA trial (22). The neoadjuvant
PAMELA trial treated 151 HER2+ breast cancer patients
with trastuzumab-lapatinib (and endocrine therapy if HR-
positive) (26). Tumor cellularity and the TILs score measured
at day 15 following anti-HER2 therapy was associated with
pathologic complete response (pCR). A combined score, CelTIL,
considering both variables was derived: CelTIL score = −0.8 ×
tumor cellularity (in %) + 1.3 × TILs (in %). The CelTIL score
was validated in the PAMELA (26) and LPT109096 (27) phase
II neoadjuvant trials as an early readout of the probability of a
pCR. High CelTIL scores identify tumors that have high immune
infiltration and reduced tumor cellularity (22).
In a third study, the CelTIL score was performed in tumor
samples of 196 patients with early-stage HER2-positive disease
treated with standard trastuzumab-based chemotherapy from
the NeoALTTO phase III trial (28). This study randomized
455 women with HER2-positive early breast cancer to lapatinib
(Arm A), trastuzumab (Arm B), or trastuzumab and lapatinib
(Arm C) for 6 weeks, followed by an assigned anti-HER2
treatment combined with paclitaxel weekly. The CelTIL score
was independently associated with event free survival, overall
survival, and pCR (29). Early and absolute changes in the CelTIL
score following neoadjuvant therapy were associated with tumor
shrinkage at surgery in other three neoadjuvant trials (30).
Taken together, these results demonstrated that high TILs and
low tumor cellularity following one cycle of treatment provided
TABLE 2 | Primary and secondary objectives and endpoints.
Primary objective Primary endpoint
To evaluate if one dose of U3-1402 increases the value of the CelTIL score
between baseline and post-treatment samples in all included patients with early
breast cancer.
Mean change in the CelTIL score per central assessment in paired samples after one
dose of U3-1402 at C1D21 (±3).
CelTIL score = −0.8 × tumor cellularity (in %) + 1.3 × TILs (in %). The minimum and
maximum unscaled CelTIL scores will be −80 and 130. This unscaled CelTIL score
will then be scaled to reflect a range from 0 to 100 points.
Secondary objectives Secondary endpoints
To identify a significant increase in the CelTIL score after one dose of U3-1402
between baseline and post-treatment samples within each of the four ERBB3
cohorts.
Mean change in the CelTIL score at C1D21 of treatment in paired samples in ultralow,
low, medium, and high ERBB3 cohorts.
To determine the association of the levels of baseline ERBB3 expression with
changes in the CelTIL score after one dose of U3-1402 in all patients and within
each ERBB3 cohort.
Correlation between ERBB3 mRNA baseline levels and changes in the CelTIL score
at C1D21 in paired samples in all patients and in ultralow, low, medium, and high
ERBB3 cohorts.
To determine the association of HER3 IHC expression with changes in the
CelTIL score after a single dose of U3-1402 in all patients and within each
ERBB3 cohort.
Correlation between HER3 IHC levels per central assessment and changes in the
CelTIL score at C1D21 in paired samples in all patients and in ultralow, low, medium,
and high ERBB3 cohorts.
To evaluate the changes in CelTIL across the four PAM50 intrinsic subtypes. CelTIL score at the C1D21 score according to intrinsic subtype: Luminal A, Luminal
B, HER2-enriched, and Basal-like subtypes.
To evaluate the antiproliferative activity of one dose of U3-1402 between
baseline and post-treatment samples.
Complete Cell Cycle Arrest (CCCA) determined per central assessment by IHC Ki67<
2.7% at C1D21.
Differences in differential expression [mean suppression = 100–[geometric mean
(post-treatment/pre-treatment 100)]] of proliferative genes (BIRC5, CCNB1, CDC20,
CDCA1, CEP55, KNTC2, MKI67, PTTG1, RRM2, TYMS, and UBE2C).
To evaluate the association of ERBB3 mRNA expression with HER3 IHC
expression.
Correlation coefficients between both biomarkers.
To evaluate the changes of HER3 expression. HER3 IHC at baseline, at D3-D7 (optional), C1D21.
To describe the safety and tolerability of U3-1402. Type, incidence, severity (as graded by the NCI CTCAE v. 5.0), seriousness, and
attribution to the study medications of AEs and any laboratory abnormalities.
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independent and additional predictive information in patients
with primary breast cancer following neoadjuvant treatment, also
suggesting that CelTIL could be a surrogate for treatment efficacy
in the neoadjuvant setting.
Secondary endpoints, summarized in Table 2, include
mean change in the CelTIL score in ultralow, low, medium,
and high ERBB3 cohorts, correlation between ERBB3 mRNA
and HER3 IHC baseline levels and changes in the CelTIL
score, the CelTIL score according to PAM50 intrinsic
subtype, antiproliferative activity, and safety. Exploratory
and translational research endpoints include the assessment of
predictive and prognostic biomarkers.
FIGURE 2 | Measurement of ERBB3 expression in breast cancer using the nCounter platform. (A) Box plots of ERBB3 gene expression in breast tumors as classified
by hormone receptor and HER2 expression and intrinsic subtype. (B) Unsupervised hierarchical clustering using the 50 PAM50 genes and ERBB3 (rows) and 1,580
tumor samples (columns). Each colored square on the heatmap represents the relative median signature score for each sample with the highest expression being red,
the lowest expression being green, and the average expression being black. (C) Pearson correlation between ERBB3, single genes, and PAM50 gene expression
signatures evaluated in breast cancer samples.
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FIGURE 3 | Comparing ERBB3 expression across datasets (A) Evaluation of ERBB3 cutoff in breast cancer samples from patients with early breast cancer included
in IN-HOUSE, METABRIC, and TCGA. (B) Proportion of samples in each immunohistochemistry subtype based on the ERBB3 cohort. Each bar is colored according
to the ERBB3 distribution in each cohort. (C) Correlation coefficients of proportions of tumor samples within each quartile based on the IHC subtype between the
three datasets. (D) Scatter plots of ERBB3 vs. ESR1 expression for samples from METABRIC, IN-HOUSE, and TCGA cohorts, colored by subtype. The three
horizontal lines indicate the cutoffs of each cohort. Discontinued line in each figure represents the regression line. Pearson correlation coefficient (r) with significance
(p-value) is presented in each figure.
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Measuring ERBB3 mRNA
Each patient will be assigned to one of the four cohorts
according to their ERBB3 mRNA expression in the baseline
sample determined by the nCounter Platform. The cutoffs to be
used in this trial were determined as follows.
To date, we have analyzed ERBB3 mRNA using the nCounter
platform in 1,600 tumor samples using formalin-fixed paraffin-
embedded tumor samples with IHC data. Among these samples
with IHC data, 65% were HR-positive and 18% were HER2-
positive. The IHC subtype distribution is as follows: (1) 51.9%
HR-positive/HER2-negative, (2) 29.9% triple-negative breast
cancer (TNBC), (3) 13.5% HR-positive/HER2-positive, and (4)
4.7% HR-negative/HER2-positive.
In this nCounter dataset, the range of ERBB3 mRNA
expression has an 18.6-fold difference in gene expression (i.e.,
from the lowest to the highest ERBB3 value), and the interquartile
range is 1.5 (in log base 2), which is equal to a difference in
expression of 2.9-fold.
Large expression variability across and within each IHC-
based and PAM50 subtype was observed. ERBB3 expression
was statistically significantly higher in HR-positive tumors
(P < 0.001; Figure 2A). ERBB3 expression varied statistically
significantly according to the intrinsic subtype (P < 0.001;
Figure 2A), with the Luminal A subtypes showing the highest
median expression, followed by the Luminal B, HER2-enriched,
and Basal-like.
Using quartiles, the proportion of ERBB3-high tumors within
each IHC subtype ranged from 4% in TNBC to 36% in
HR+/HER2-negative when percentile 75th in the combined
matrix was used as the cutoff to define ERBB3-high (Figure 2A).
Next, we explored the association of ERBB3 expression
with PAM50 breast cancer-related genes in the combined
matrix (Figure 2B). As expected, ERBB3 high correlated
[correlation coefficients [r] > 0.50] with a group of five genes,
including ESR1 and FOXA1, which are significantly enriched
in luminal and hormone response biology. Concordant with
this single-gene analysis, moderate correlation (r = 0.53)
was found between ERBB3 and PAM50 Luminal A signature
and negative correlation (r = −0.25) between ERBB3 and
PAM50 Basal-like, proliferation, and risk of recurrence signatures
(Figure 2C).
Evaluating ERBB3 Expression in
Independent Datasets
In order to examine the consistency of the cutoff points, results
from the in-house nCounter dataset were compared to two
independent cohorts (i.e., METABRIC and TCGA datasets).
METABRIC includes 1,992 breast cancer samples analyzed by
the Illumina HT 12 IDATS platform, and TCGA includes 1,101
breast cancer samples analyzed by HiSeq Illumina sequencers
(Figure 3A).
Using quartiles, Figure 3B shows the proportion of tumors
within each quartile based on their IHC subtype between our
in-house dataset, METABRIC, and TCGA. Figure 3C shows
the correlation coefficients among the three datasets in the
different IHC-group tumors. In HR-positive/HER2-negative, the
correlation coefficients of the proportions between the three
datasets were remarkably similar. In the other subtypes, the
correlation coefficients among the datasets were between 0.49
and 0.99. A relationship between ERBB3 and ESR1 expression
was seen to be moderately correlated across the three datasets
(Figure 3D); the correlation coefficients among the datasets were
between 0.51 and 0.59.
Statistical Analysis
The study would require a sample size of 72 (number of pairs
samples) to achieve a power of 80% using a level of significance
of 5% (two sided), for detecting a mean difference between pairs
of 13 CelTIL score. It is assumed that the standard deviation of
the differences is 38.6, which is the standard deviation observed
in 403 patients with CelTIL data across the four SOLTI trials (30).
Assuming a 10% drop-out or lack of available tissue, 80 patients
will be recruited.
No formal statistical comparison will be carried out between
cohorts. Statistical analyses will be performed to estimate the
proportions or means (or medians) for all variables including
confidence interval calculations.
CONCLUSION
We propose the TOT-HER3 study, the first window of
opportunity trial to evaluate the biological effect of patritumab
deruxtecan in patients with HR-positive/HER2-negative early
breast cancer. High ERBB3 mRNA gene expression is observed
across all subtypes of breast cancer, although it predominates
in HR-positive/HER2-negative disease suggesting a role for
HER3 directed therapies in this disease. We will analyze
ERBB3 expression using a clinically applicable assay in FFPE
primary tumors.
This information can provide insight for improving the
design of future clinical trials in the HR-positive/HER2-
negative breast cancer through the selection of patients
who will mostly benefit from this drug. The use of a
quantitative method such as ERBB3 mRNA expression,
which offers the opportunity to identify different cutoffs,
might potentially improve treatment personalization. In
addition, the results of TOT-HER3 could help identify patients
most likely to benefit from HER3 directed ADCs across
cancer types.
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